Gavilimomab
From Infogalactic: the planetary knowledge core
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Mouse |
Target | CD147 |
Identifiers | |
CAS Number | 244096-20-6 ![]() |
ATC code | none |
![]() ![]() |
Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2]
It was originally developed by Abgenix,[1] which was later acquired by Amgen.
References
- ↑ 1.0 1.1 findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibodies for tumors
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs